Studies analyzing the role of antiendothelial cell antibodies (AECAs) in large series of kidney transplant recipients are scarce, and HLA, MHC (major histocompatibility complex) class I−related chain A (MICA), and angiotensin II type 1 receptor have not been formally excluded as targets.